• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr Mitzi Joi Williams: We Need More Education on MS Presentation in Minority Populations

Video

Mitzi Joi Williams, MD, FAAN, medical director and CEO, Joi Life Wellness Neurology Clinic, addresses several reasons that have potential to delay a correct multiple sclerosis (MS) diagnosis in minority patient populations, including social determinants of health.

Mitzi Joi Williams, MD, FAAN, medical director and CEO, Joi Life Wellness Neurology Clinic, in an interview from this year’s American Academy of Neurology annual meeting, addresses several reasons that have potential to delay a correct multiple sclerosis (MS) diagnosis in minority patient populations, including social determinants of health (SDOH).

Transcript

Beyond SDOH, what might lead to a delayed MS diagnosis in minority and underserved patient populations?

I think that the biggest reason that we may see delay in diagnosis is social determinants of health. But I think also, there needs to be more education amongst the general medical community. When most of us came through training, we thought of MS as a disease of young white European women or women of European descent, and so because the symptoms of MS can mimic many other conditions—they often may resolve after a couple of weeks—it's important for people to think about MS in these populations and to recognize that anyone can get MS. And just like it may be high on the list for a young White woman presenting with certain symptoms, it should also be high on the list for people of Black and African American, as well as Hispanic and Latinx, descent.

Related Videos
A new study finds law enforcement presence in emergency departments may disrupt care. Lead author Prashasti Bhatnagar discusses policy and training solutions.
Jennifer Snow, MPA, NAMI
Jennifer Snow, MPA, NAMI
Dr Debra Patt
Most employees are unprepared to shop for coverage on their own, underscoring the need for stronger decision tools and consumer protections.
Experts warn that ICHRAs could either stabilize or destabilize the individual market, depending on which workers employers shift into these plans.
Aleata Postell, SVP of pharmacy business development, CenterWell Pharmacy
ASCO GI 2026 Recap
Jo Varshney, PhD, DVM, CEO and founder of VeriSIM Life
Dr Marco del Riccio
Related Content
© 2026 MJH Life Sciences
AJMC®
All rights reserved.